Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Recruiting

Phase 1

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic TumorsStudy With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Sponsor:

AbbVie

Code:

NCT04777994

Conditions

Advanced Solid Tumor Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ABBV-CLS-484

Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)

Programmed Cell Death-1 (PD-1) Inhibitor

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-28. This information was provided to ClinicalTrials.gov by AbbVie on 2025-03-25.